Imatinib
Orphan DrugFDA Approved
Description
Imatinib is a tyrosine kinase inhibitor used to treat certain cancers. It targets specific proteins that drive the growth of cancer cells. It is used in the treatment of inherited soft tissue tumors.
Indications & Therapeutic Use
Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), inherited soft tissue tumor
Linked Diseases:
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Imatinib
| Generic Name | Imatinib |
| Brands | 1 brand available |
| Active Ingredient | Imatinib mesylate |
| Drug Class | Chronic Myeloid Leukemia (CML) |
| Manufacturer | Novartis |
| Dosage Forms | Tablet |
| Medical Code | L01XE01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00030689 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes